Jomed's Global Positioning
Executive Summary
Over the past several years, Swiss Jomed has been one of the few small European stent companies to grow into a major cardiovascular device company. Last year's successful IPO was testimony to the company's strong sales growth. But it was two deals the company did following soon after the IPO, the acquisitions of US-based MediDyne and EndoSonics, that will test whether Jomed is ready to break out of the pack and compete on a truly global scale with medical device giants such as Guidant and Medtronic.
You may also be interested in...
Millimed's Play in Interventional Neurology
Ten years ago, a group of executives launched Jomed with the thought of challenging the large cardiovascular device companies as a global player. Jomed never quite achieved that goal--though it came close. Now, with an innovative NO-loaded balloon, some former Jomed executives hope to do in interventional neurology what they tried to do in interventional cardiology.
Millimed models Jomed in interventional neurology
Former Jomed CEO Tor Peters is back, trying to build another major device company, this time in interventional neurology and modeled after the strategy he used at Jomed.
Abbott Moves One Way in Cardiovascular Devices, Another in Orthopedics, To Get To the Same Place
Abbott Laboratories broke into the spinal market with its acquisition of Spinal Concepts, and expanded its interventional cardiology product line by acquiring Jomed's coronary and peripheral interventional product lines. Both deals reflect the increasing convergence in medical devices of drug and device therapies.